Out now in @JCO_ASCO!
Can we better identify which patients with RRMM will experience early treatment failure vs durable benefit from bispecific T-cell engagers?
Across 943 treatment initiations in the US Multiple Myeloma Immunotherapy Consortium cohort, we developed a simple, pragmatic, and reproducible prognostic model: the CHARGE index.
We then externally validated CHARGE in an independent, multicenter cohort from the @IMFmyeloma data registry.
https://t.co/OHPrhfOlLE
🧵 1/
Topline findings 👇
-Can tec+dara be initiated using schedules that differ from MajesTEC-3 without increasing immune-mediated toxicity?
-Does prophy toci reduce CRS and shorten LOS?
-Can tec/dara SUD be administered in the outpt setting?
-Does delaying dara until after tec SUD affect CRS risk?
#nerdalert 🤓! Catch my oral abstract at #ASH26. I'll be presenting our consortium's research investigating tec/dara step-up dosing. Presentation is Monday Dec 14th . https://t.co/RTN8mkA6Dd
We attempt to answer the following questions...🧵
New WolverHeme Happy Hour!!!!🎙️ @Berninini & @ajperissinotti are joined by @thisisJamesD, @drrx4L, @Papa_Heme, Jon Weiss to tackle frontline DLBCL: we critically appraise frontMIND and intertwine POLARIX, and EPCORE-DLBCL2. What’s ready to change practice? https://t.co/o25vSZo327
➡️ Last year we published use of #pocketdex in patients on teclistamab.
🧠 🤓 Now hot off the press as a full manuscript, see how dex for low-grade CRS is safe and effective with talquetamab
https://t.co/H8ODIQ08Xl
💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio#BloodNeoplasia https://t.co/pOY7cJCQFD
#Myeloma Paper of the Day: Analysis from US Multiple Myeloma Immunotherapy Consortium of real-world elranatamab data finds median PFS & OS 4.3 & 14.6 mos; elevated LDH & low Hgb predict poor outcomes; prior BCMA exposure reduced response depth: https://t.co/cWilnMWaAI. #mmsm
Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. https://t.co/TNHq2yGj7V
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.
"Can I get MMR 💉 on dara-len maintenance?"
Short answer: 💯%, it seems!
Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
Earlier in the year we published efficacy of #pocketdex in patients receiving teclistamab, Sunday we present our group’s second pharmD led oral abstract at #ASH25 validating the safety of dex with talquetmab. Again, you don’t need toci for low grade CRS! https://t.co/yh4ZBclxwP